Itraconazole
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Using no specialised skill here — this is a direct documentation/report-generation task governed entirely by the prompt’s explicit template, not a coding or debugging task.
Itraconazole: From Fungal Infections to Pneumocystosis
One-Sentence Summary
Itraconazole is a triazole antifungal agent originally used to treat fungal infections; the evidence pack does not specify its original UK-approved indication text. The TxGNN model predicts it may be effective for Pneumocystosis, with a prediction score of 99.34%, but this is currently supported only by 0 clinical trials and 20 publications, none of which are direct interventional trials for this indication — and one mechanistic study reports findings that directly contradict the plausibility of this prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in evidence pack (itraconazole is a triazole/azole antifungal; no taiwan_regulatory.licenses or drug.original_indications data available) |
| Predicted New Indication | Pneumocystosis |
| TxGNN Prediction Score | 99.34% |
| Evidence Level | L4 (mechanistic/observational evidence only; no disease-specific clinical trials; one RCT identified is for general antifungal prophylaxis, not pneumocystosis) |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for itraconazole in this evidence pack. Based on general pharmacological knowledge, itraconazole is a triazole antifungal that inhibits fungal lanosterol 14α-demethylase (a CYP51 enzyme), blocking ergosterol synthesis in the fungal cell membrane. This mechanism underlies its efficacy against a range of fungal pathogens.
Pneumocystis jirovecii (formerly P. carinii) was historically classified as a fungal organism, which superficially supports the plausibility of an azole-class antifungal being repurposed for pneumocystosis. Additionally, several of the retrieved publications describe itraconazole use in the same immunocompromised patient populations (HIV/AIDS, transplant recipients) in which pneumocystosis is a common opportunistic infection, suggesting an epidemiological rather than direct therapeutic overlap.
Important caveat: one of the retrieved publications (PMID 12606318) directly characterises the lanosterol 14α-demethylase enzyme of Pneumocystis carinii and reports that the organism is intrinsically resistant to azole antifungal medications, due to structural differences at key resistance-conferring sites. This finding is mechanistically at odds with the TxGNN prediction and should be treated as a significant caution flag rather than supporting evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 11737382 | 2001 | RCT | HIV Medicine | Double-blind, placebo-controlled Phase 3 trial of itraconazole capsules for prevention of deep fungal infections in HIV-infected patients — general antifungal prophylaxis, not pneumocystosis-specific |
| 12606318 | 2003 | Mechanism Study | Am J Respir Cell Mol Biol | Characterises Pneumocystis carinii lanosterol 14α-demethylase; reports the organism is intrinsically resistant to azole antifungals — directly contradicts the repurposing rationale |
| 2121456 | 1990 | Review | Drugs | Reviews therapy/prophylaxis of Pneumocystis carinii and other protozoan/fungal opportunistic infections, including antifungal mechanisms and dosing |
| 21418688 | 2010 | Review | BMJ Clinical Evidence | Reviews primary/secondary prophylaxis of HIV-related opportunistic infections, including Pneumocystis pneumonia |
| 8397916 | 1993 | Review | Curr Clin Top Infect Dis | Reviews prophylaxis/treatment of infections, including PCP, in bone marrow transplant recipients |
| 8016481 | 1993 | Review | Semin Respir Infect | Reviews infections, including PCP, after lung transplantation |
| 7877856 | 1994 | Review | Pathol Biol | Notes prior pneumocystosis as a predisposing factor for aspergillosis in AIDS patients |
| 36891307 | 2023 | Case Report | Frontiers in Immunology | Case of Talaromyces marneffei and Pneumocystis jirovecii coinfection in a child with STAT1 mutation |
| 19080136 | 2008 | Observational | Zhonghua Nei Ke Za Zhi | Study of pathogens and drug resistance in pulmonary infections, including PCP, among AIDS patients |
| 30429396 | 2018 | Observational | Indian J Med Microbiol | Compares respiratory fungal pathogen profiles, including PCP, in immunocompetent vs immunocompromised hosts |
UK Market Information
Itraconazole is currently not marketed in the UK per this evidence pack, with no marketing authorisations recorded (total_licenses: 0).
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: No disease-specific clinical trials support this indication, MOA and safety data are unavailable, the drug is not currently marketed in the UK, and — most importantly — a mechanistic study in the evidence pack indicates that Pneumocystis is intrinsically resistant to azole antifungals, directly challenging the biological plausibility of the TxGNN prediction.
To proceed, the following is needed:
- Resolution of the contradictory mechanistic evidence on azole resistance in Pneumocystis (PMID 12606318) before further evaluation
- Detailed mechanism of action data (MOA) for itraconazole
- MHRA/SmPC-sourced safety data (key warnings, contraindications, DDIs)
- Any UK regulatory status update, given the drug is currently unmarketed
- Disease-specific interventional or observational studies evaluating itraconazole for pneumocystosis, rather than general antifungal prophylaxis in overlapping patient populations
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.